Bio-Products & Bio-Engineering Aktiengesellschaft
Records under this name other than patents Bio-Products & Bio-Engineering Aktiengesellschaft holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Showing 1 to 10 of 10 · Back to Bio-Products & Bio-Engineering Aktiengesellschaft
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,889,624 | Thrombin-free composition containing freeze-dried, virally inactivated FXIa and serpins and/or kininogen Lapsed on the fee record Ended Nov 18, 2022 · From the USPTO record | Lapsed on the fee record | Ended Nov 18, 2022 | From the USPTO record |
| US 7,795,399 | Stable therapeutic proteins Lapsed on the fee record Ended Sep 14, 2022 · From the USPTO record | Lapsed on the fee record | Ended Sep 14, 2022 | From the USPTO record |
| US 10,047,342 | Elutriation chamber for an elutriator system Lapsed on the fee record Ended Aug 14, 2022 · From the USPTO record | Lapsed on the fee record | Ended Aug 14, 2022 | From the USPTO record |
| US 8,741,846 | Storage-stable, functionally intact fibrinogen Lapsed on the fee record Ended Jun 3, 2022 · From the USPTO record | Lapsed on the fee record | Ended Jun 3, 2022 | From the USPTO record |
| US 7,494,971 | Pharmaceutical preparations and medicines capable of generating, and/or containing, thrombin Lapsed on the fee record Ended Feb 24, 2021 · From the USPTO record | Lapsed on the fee record | Ended Feb 24, 2021 | From the USPTO record |
| US 8,268,362 | Medicinal product for the promotion of wound healing Lapsed on the fee record Ended Sep 18, 2020 · From the USPTO record | Lapsed on the fee record | Ended Sep 18, 2020 | From the USPTO record |
| US 7,371,722 | Pharmaceutical preparations and medicine capable of generating and/or containing thrombin Lapsed on the fee record Ended May 13, 2020 · From the USPTO record | Lapsed on the fee record | Ended May 13, 2020 | From the USPTO record |
| US 6,372,221 | Immunogenic constructs comprising flaviviruses or flavivirus derivatives Term ended Term ended Dec 12, 2017 · From the USPTO record | Term ended | Term ended Dec 12, 2017 | From the USPTO record |
| US 6,034,222 | Method for the separation of recombinant pro-factor IX from recombinant factor IX Term ended Term ended Oct 4, 2015 · From the USPTO record | Term ended | Term ended Oct 4, 2015 | From the USPTO record |
| US 5,895,653 | Adjuvant based on colloidal iron compounds Term ended Term ended no later than Apr 20, 2019 · Low confidence | Term ended | Term ended no later than Apr 20, 2019 | Low confidence |